Lazarus J H, Littley M D, Phillips D I
Department of Medicine, University of Wales College of Medicine, Llandough Hospital, UK.
J Hum Hypertens. 1988 Oct;2(3):191-4.
To determine if the calcium channel blocking agent, nitrendipine, is effective as monotherapy we have performed a double-blind placebo-controlled crossover trial using 20 mg once daily or twice daily in 19 mild to moderate hypertensive patients. Blood pressure was measured by a random zero (RZ) sphygmomanometer and at home using the Remler semiautomatic BP recorder. The BP (RZ) was significantly reduced by twice daily nitrendipine compared to placebo (from 163/99 +/- 20/6 mmHg to 140/90 +/- 15/9 mmHg). Once daily drug administration reduced systolic BP only (163 +/- 20 to 144 +/- 17 mmHg). Remler BP confirmed that the maximum systolic and diastolic BP lowering effect was in the twice daily group while once daily drug did produce a significant lowering of BP but less than the twice daily dosage. This study suggests that twice daily nitrendipine caused a greater decrease in BP and was more consistent than once a day. The emergence of a new generation of automatic BP recorders should improve the evaluation of once daily therapeutic agents.
为确定钙通道阻滞剂尼群地平作为单一疗法是否有效，我们对19例轻至中度高血压患者进行了一项双盲安慰剂对照交叉试验，每日服用一次或两次20毫克尼群地平。血压通过随机零点（RZ）血压计测量，并在家中使用雷姆勒半自动血压记录仪测量。与安慰剂相比，每日两次服用尼群地平可使血压（RZ）显著降低（从163/99±20/6毫米汞柱降至140/90±15/9毫米汞柱）。每日一次给药仅降低收缩压（163±20至144±17毫米汞柱）。雷姆勒血压记录仪证实，每日两次服药组的收缩压和舒张压降低效果最大，而每日一次服药确实使血压显著降低，但低于每日两次服药剂量。这项研究表明，每日两次服用尼群地平导致的血压下降幅度更大，且比每日一次更稳定。新一代自动血压记录仪的出现应能改善对每日一次治疗药物的评估。
